Published on August 14, 2013 at 7:15 AM
Pfizer will have access to Sanford-Burnham's team of world-class scientists and translational infrastructure dedicated to finding new approaches to targeting disease. Collaborating with researchers at a major pharmaceutical company will help Sanford-Burnham achieve its mission of translating high-impact science into new therapies. "This important collaboration focuses our tremendous scientific and translational firepower on a major medical problem - complications of obesity-related diabetes. Working with Pfizer, we can more quickly bridge the gap between basic and translational research," said Stephen Gardell, Ph.D., senior director of scientific resources at Sanford-Burnham Medical Research Institute at Lake Nona.
The Prebys Center houses Sanford-Burnham's state-of-the-art screening facility established to accelerate the rate of commercialization of basic research in an independent medical research setting. Sanford-Burnham's drug discovery capabilities include: ultra-high throughput screening, high-content screening, phenotypic screening, and target deconvolution technologies. The Prebys Center is led and staffed by industry-trained professionals who work closely with Sanford-Burnham investigators and industry collaborators to translate scientific findings into actionable drug discovery projects.
Source: Sanford-Burnham Medical Research Institute